- Conditions
- Methicillin Resistant Staphylococcus Aureus, Osteomyelitis Acute, Septic Arthritis, Orbital Cellulitis, Facial Cellulitis, Mastoiditis, Cervical Adenitis, Retropharyngeal Abscess, Peritonsillar Abscess
- Interventions
- Trimethoprim Sulfamethoxazole
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 2 Months to 18 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced May 21, 2026, 10:11 PM EDT